Italia markets closed

Valneva SE (VLA.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
3,1550+0,0880 (+2,87%)
Alla chiusura: 05:36PM CET

Valneva SE

6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
https://valneva.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno719

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Thomas LingelbachPresident, CEO & Director783,68kN/D1963
Mr. Peter BuhlerChief Financial Officer519,98kN/D1971
Mr. Frederic JacototVP of Legal & IP, General Counsel, and Corporate Secretary298,48kN/D1966
Mr. Franck Grimaud MBAChief Business Officer389,29kN/D1967
Dr. Juan-Carlos Jaramillo M.D.Chief Medical Officer472,53kN/D1972
Ms. Dipal PatelChief Commercial Officer759,39kN/D1975
Mr. Vincent DequenneChief Operating OfficerN/DN/DN/D
Mr. Joshua Drumm Ph.D.Vice President of Investor RelationsN/DN/DN/D
Ms. Laetitia Bachelot-FontaineVP of Global Communications & European Investor RelationsN/DN/DN/D
Ms. Petra PesendorferChief People OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Governance aziendale

L'ISS Governance QualityScore di Valneva SE al 1 marzo 2024 è 9. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 7; diritti degli azionisti: 9; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.